As we continue to take on a leadership role in the development of cell therapies, the commercialization of our products, whether alone or in partnership with large pharmaceutical companies, will be integral to our strategy. We are always looking out for additional leadership to join our team with relevant experience, and the recent appointment of Martyn Greenacre to NeoStem’s Board of Directors is a prime example.
Experience in European Markets
In 1973, Martyn joined SmithKline & French Pharmaceuticals where he held positions of increasing responsibility and oversaw the strategic direction and operational management of all pharmaceutical subsidiaries in Western Europe. He also oversaw the execution of the merger of SmithKline Beecham Corp. and Beecham Group p.l.c. pharmaceutical operations in Europe. We are excited to add Martyn’s experience in Europe to our Board due to the potential of the European cell therapy market. His addition supports NeoStem’s opportunity to move into this region, should we want to in the future.
Mergers and Divestitures
As we come to the end of a year that featured two strategic mergers for NeoStem, Progenitor Cell Therapy, LLC and Amorcyte, Inc, and look ahead to other strategic opportunities for the company, developing our M & A expertise continues to be critical. Another key example of Martyn’s pharmaceutical business expertise is his tenure as President and Chief Executive Officer of Zynaxis Inc, a biopharmaceutical company from 1993 to 1997. There, he was responsible for the critical acquisition of Secretech, Inc., divesting a non-performing business, Zymmune™, and negotiating a strategic merger.
Strategic Partnerships and Financing
Martyn’s experience in developing strategic partnerships to drive product candidates forward is exemplified by his time at Delsys Pharmaceutical Corporation, a formulation and drug delivery system company. From 1997 to 2001, he served as Chief Executive Officer and Director of Delsys, helping to raise more than $50 million in equity and partnership financing and forming three development partnerships with pharmaceutical leaders; SmithKline Beecham, Warner-Lambert and Glaxo Wellcome.
Board and Management Experience
Martyn’s extensive board and management experience in the pharmaceutical industry and beyond makes him an asset to our corporate governance. Martyn has served as Chairman of the Board of BMP Sunstone Corporation, which was acquired by Sanofi-Aventis, and Chairman of Life Mist Technologies, Inc., a privately-held fire suppression equipment company. He also served as a director of Cephalon Inc., a biopharmaceutical company that was acquired by Teva Pharmaceutical Industries. He currently has the role of Chairman of the Board of Acusphere, Inc., and sits on the board of Curis, Inc. Martyn served as President and Chief Executive Officer of Zynaxis Inc., and was Chairman, Europe, for SmithKline Beecham Pharmaceutical Company.